US20100197962A1 - Use of Neboglamine in the Treatment of Toxicodependency - Google Patents

Use of Neboglamine in the Treatment of Toxicodependency Download PDF

Info

Publication number
US20100197962A1
US20100197962A1 US12/067,390 US6739006A US2010197962A1 US 20100197962 A1 US20100197962 A1 US 20100197962A1 US 6739006 A US6739006 A US 6739006A US 2010197962 A1 US2010197962 A1 US 2010197962A1
Authority
US
United States
Prior art keywords
neboglamine
use according
pharmaceutically acceptable
medicament
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/067,390
Inventor
Francesco Makovec
Gianfranco Caselli
Lucio Claudio Rovati
Antonio Giordani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rottapharm SpA
Original Assignee
Rottapharm SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm SpA filed Critical Rottapharm SpA
Publication of US20100197962A1 publication Critical patent/US20100197962A1/en
Assigned to ROTTAPHARM S.P.A. reassignment ROTTAPHARM S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CASELLI, GIANFRANCO, GIORDANI, ANTONIO, MAKOVEC, FRANCESCO, ROVATI, LUCIO CLAUDIO
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Definitions

  • the present invention relates to a novel use of (S)-4-amino-N-(4,4-dimethylcyclohexyl)glutamic acid (CR 2249-neboglamine) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for use in the treatment of toxicodependency induced by drugs such as Central Nervous System (CNS) sedatives such as opiates, benzodiazepines, barbiturates, alcohol, stimulants such as amphetamines and cocaine, and hallucinogens such as LSD, mescalin, cannabis (marijuana) or fencyclidine.
  • CNS Central Nervous System
  • psychological dependency means an irresistible impulse (compulsion) to continue self-administering the drug in order to find pleasure.
  • the psychological dependency is the most important factor in their compulsive use.
  • the term “physical dependency” means a state of habituation to the drug accompanied by tolerance and that is manifested by abstinence syndromes.
  • Tolerance is the need to increase the dose of the drug in order to obtain the same effects as were initially obtained with lower doses; the abstinence syndrome is characterized by painful physical sensations that are manifested when the taking of the drug is stopped.
  • CNS sedatives such as opiates, benzodiazepines, barbiturates and alcohol, which also all induce physical dependency and tolerance
  • CNS stimulants for instance amphetamine and cocaine which induce physical dependency to a minor extent, if at all
  • hallucinogens such as LSD, mescalin, cannabis (marijuana) and fencyclidine.
  • neboglamine (CR 2249) has been shown to have significant modulatory properties on the glycine site (strychnine-insensitive) coupled to the NMDA receptor complex [Lanza et al., Neuropharmacology 36, 1057-64 (1997)], and also advantageous properties of promoting memory and learning in various animal models [Garofalo et al. J. Pharm. Pharmacol. 48, 1290-97 (1996)].
  • the facilitatory activity exerted by neboglamine on the NMDA receptor complex should be of therapeutic use in conditions of glutamatergic hypo functionality.
  • NMDA receptor complex may be involved in a variety of functional responses to cocaine, for instance locomotor activity, dependency (continued reinforcement of self-administration), tolerance and toxicity (Rockhold R. W., Progress in Drug Research 50: 155-92, 1998).
  • glycine is capable of inhibiting the locomotor hyperactivity, tolerance and dependency induced by morphine in mice (K. W. Shin et al., Arch. Pharm. Res. 26: 1074-1078, 2003).
  • neboglamine was evaluated in animal experimental models that may be considered as predictive for the evaluation of toxicodependency induced by various drugs such as cocaine, morphine and benzodiazepines, which are widely representative of the syndromes caused by toxicodependency.
  • the motor activity was measured with a video camera and recorded using the Videotrack 512 system as described by Garofalo (J. Pharm. Pharmacol. 48: 1290-1297, 1996).
  • Physiological saline, neboglamine (30 mg/kg) or glycine (300 mg/kg) were administered via the i.p. route 30 minutes before physiological saline, morphine (10 mg/kg s.c.) or cocaine (20 mg/kg s.c.).
  • the locomotor activity was recorded for 15 minutes and the total distance covered (in cm) by the animal was recorded by the computer connected to the video camera. The results thus obtained are collated in Table 1.
  • Neboglamine (30 mg/kg) or physiological saline were administered via the i.p. route 30 minutes before morphine (10 mg/kg s.c.) for 6 days. On the seventh day, the test was performed, as described in the preceding experiment, in comparison with a group of animals treated with the same dose of morphine given acutely only on the 7th day (final day of the, experiment). The results thus obtained are collated in Table 2.
  • Chronic treatment with morphine induces an increase in the motor activity of the rat, compared with the acute effect of the drug, by about 50% (128.6% as opposed to 80.3%).
  • Chronic pre-treatment with neboglamine (30 mg/kg i.p for 7 days) succeeds in almost completely antagonizing (70.8%) the development of the inverse tolerance induced by the chronic treatment with morphine.
  • the rat placed in one of the closed quadrants, had free access to all 4 of the quadrants (2 open and 2 closed) for a period of 5 minutes.
  • a compound with anxiolytic activity produces a percentage increase in the time spent in the free quadrants.
  • Physiological saline 40 100.0 Acute diazepam (D) 5 105 262.5 Chronic diazepam (D-C) 5 ⁇ 2 ( ⁇ 7 days) + 5 (D) 58 145.0 Acute neboglamine (N) 30 51 127.0 Physiological (D-W) — 15 37.5 Neboglamine+ (D-C) 30 ⁇ 2 ( ⁇ 7 days) + 30 + 5 (D) 77 192.5 Neboglamine (D-W) — 44 110.0 Note: Physiological (D-W) is the group treated with diazepam for 7 days and retested 40 hours later with physiological saline. Neboglamine (D-W) is the group treated with diazepam and neboglamine for 7 days and retested 40 hours later with physiological saline
  • Neboglamine displays non-significant anxiolytic activity (127% compared with the controls). However, its co-administration with diazepam does not reduce tolerance (192.5% effect compared with the control). In addition, the co-administration of neboglamine was shown to inhibit the abstinence crisis induced by stoppage of the chronic treatment with diazepam [110% of effect for the group N-(D-W) as opposed to 37.5% of effect for the group (D-W)].
  • compositions comprising as active principle neboglamine or the racemic mixture thereof, in native form or pharmaceutically acceptable salts thereof.
  • compositions for using the compounds according to the invention may be prepared using conventional techniques.
  • the formulations include those suitable for oral use, for instance capsules, tablets, suspensions, emulsions, solutions; sterile solutions for parenteral use (including subcutaneous, intramuscular and intravenous administration), or preparations for topical or rectal use or other forms suitable for obtaining the desired therapeutic effect, for example solid formulations for oral use with delayed action, which allow a slow release of the active principle over time.
  • Substances commonly used in the pharmaceutical field as excipients, binders, disintegrants and substances capable of stimulating transdermal absorption may be used together with the active principle in the pharmaceutical formulation.
  • Neboglamine compounds such as the racemic mixture thereof, may thus be used in native form or as pharmaceutically acceptable salts.
  • neboglamine it is preferably the sodium or potassium salt or the hydrochloride.
  • the effective therapeutic amount of neboglamine to be used for the treatment of drug-induced toxicodependency should be between 10 and 600 mg and preferably from 30 to 300 mg per day of active principle, depending on the specific conditions of the treated patient, and the individual response to the treatment, the age and the weight of the patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of neboglamine, (S)-4-amino-N(4,4-dimethyl-cyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the treatment of toxicodependency induced by drugs such as CNS sedatives such as opiates, barbiturates, benzodiazepines, alcohol, stimulants such as amphetamines and cocaine, and hallucinogens such as LSD, mescalin, cannabis (marijuana) or fencyclidine.

Description

  • The present invention relates to a novel use of (S)-4-amino-N-(4,4-dimethylcyclohexyl)glutamic acid (CR 2249-neboglamine) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for use in the treatment of toxicodependency induced by drugs such as Central Nervous System (CNS) sedatives such as opiates, benzodiazepines, barbiturates, alcohol, stimulants such as amphetamines and cocaine, and hallucinogens such as LSD, mescalin, cannabis (marijuana) or fencyclidine.
  • The term “toxicodependency”, whether physical or psychological, means the continued and totally implicit use of a drug. Such a use involves the risk of physical damage and the need to stop or limit the consumption of the substance, whether or not the drug taker is in agreement.
  • The term “psychological dependency” means an irresistible impulse (compulsion) to continue self-administering the drug in order to find pleasure. For certain drugs, the psychological dependency is the most important factor in their compulsive use.
  • The term “physical dependency” means a state of habituation to the drug accompanied by tolerance and that is manifested by abstinence syndromes.
  • Tolerance is the need to increase the dose of the drug in order to obtain the same effects as were initially obtained with lower doses; the abstinence syndrome is characterized by painful physical sensations that are manifested when the taking of the drug is stopped.
  • The substances commonly used by drug takers all induce psychological dependency, while others (the majority) also induce physical dependency.
  • The following groups may be distinguished: CNS sedatives such as opiates, benzodiazepines, barbiturates and alcohol, which also all induce physical dependency and tolerance; CNS stimulants, for instance amphetamine and cocaine which induce physical dependency to a minor extent, if at all; hallucinogens such as LSD, mescalin, cannabis (marijuana) and fencyclidine.
  • On the basis of published preclinical data, the compound neboglamine (CR 2249) has been shown to have significant modulatory properties on the glycine site (strychnine-insensitive) coupled to the NMDA receptor complex [Lanza et al., Neuropharmacology 36, 1057-64 (1997)], and also advantageous properties of promoting memory and learning in various animal models [Garofalo et al. J. Pharm. Pharmacol. 48, 1290-97 (1996)]. The facilitatory activity exerted by neboglamine on the NMDA receptor complex should be of therapeutic use in conditions of glutamatergic hypo functionality.
  • It has been suggested that the NMDA receptor complex may be involved in a variety of functional responses to cocaine, for instance locomotor activity, dependency (continued reinforcement of self-administration), tolerance and toxicity (Rockhold R. W., Progress in Drug Research 50: 155-92, 1998).
  • It has also recently been demonstrated that glycine is capable of inhibiting the locomotor hyperactivity, tolerance and dependency induced by morphine in mice (K. W. Shin et al., Arch. Pharm. Res. 26: 1074-1078, 2003).
  • Thus, neboglamine was evaluated in animal experimental models that may be considered as predictive for the evaluation of toxicodependency induced by various drugs such as cocaine, morphine and benzodiazepines, which are widely representative of the syndromes caused by toxicodependency.
  • In the first model used, the inhibitory effect of neboglamine and glycine on the hypermotility induced by cocaine and morphine in rats was evaluated.
  • The motor activity was measured with a video camera and recorded using the Videotrack 512 system as described by Garofalo (J. Pharm. Pharmacol. 48: 1290-1297, 1996).
  • Physiological saline, neboglamine (30 mg/kg) or glycine (300 mg/kg) were administered via the i.p. route 30 minutes before physiological saline, morphine (10 mg/kg s.c.) or cocaine (20 mg/kg s.c.).
  • The locomotor activity was recorded for 15 minutes and the total distance covered (in cm) by the animal was recorded by the computer connected to the video camera. The results thus obtained are collated in Table 1.
  • TABLE 1
    Inhibitory activity of neboglamine and glycine on the
    locomotor hyperactivity induced by cocaine and morphine
    Total % increase vs.
    Dose distance physiological % inhibition vs.
    Treatment (mg/kg) (cm) saline the drug (D)
    Physiological F + F 3300 — —
    saline (F)
    Neboglamine 30 + F   3150 (−)4.5 —
    (N)
    Glycine (G) 300 + F    2900 (−)12.1 —
    Cocaine (C)   F + 20 5800 75.7 —
    Morphine (M)   F + 10 5300 60.6 —
    N + C 30 + 20 3600 9.1 88.0(1)
    N + M 30 + 10 3750 13.6 77.5(1)
    G + M 300 + 10  4250 28.8 52.5(2)
    ( 1 ) The % inhibition is calculated by the formula : [ D - ( D + N ) ] D - F × 100
    ( 2 ) The % inhibition is calculated by the formula : [ D - ( D + G ) ] D - F × 100
  • From the data given in Table 1, it may be seen that both cocaine and morphine show a marked increase in locomotor activity (75.7% and 60.6%, respectively), whereas neboglamine and glycine do not significantly alter the spontaneous motility of the animal.
  • The motor activity accelerated by both the drugs cocaine and morphine is almost completely antagonized by doses of 30 mg/kg i.p. of neboglamine (88% and 77.5%, respectively). Glycine also inhibits the morphine-induced hyperkinetic activity, but with a smaller effect (52.5%) and at doses 10 times higher (300 mg/kg as opposed to 30 mg/kg of neboglamine).
  • In a second experiment, the capacity of neboglamine to inhibit the increased sensitivity (inverse tolerance) induced in rats was evaluated by chronic treatment with morphine.
  • Neboglamine (30 mg/kg) or physiological saline were administered via the i.p. route 30 minutes before morphine (10 mg/kg s.c.) for 6 days. On the seventh day, the test was performed, as described in the preceding experiment, in comparison with a group of animals treated with the same dose of morphine given acutely only on the 7th day (final day of the, experiment). The results thus obtained are collated in Table 2.
  • TABLE 2
    Inhibitory activity of neboglamine on the inverse tolerance
    induced by chronic treatment with morphine in rats
    % increase % inhibition of
    Total vs. the
    Dose distance physiological hypersensitivity
    Treatment (mg/kg) (cm) saline of morphine
    Physiological — 2800 — —
    saline (F)
    Morphine 10 (s.c) 5050 80.3 —
    Chronic morphine 10 (s.c.) × 6400 128.6 —
    (MC) 7 days
    CM + neboglamine 10 (s.c.) + 3850 37.5 70.8(1)
    (N) 30
    (N i.p.) ×
    7 days
    ( 1 ) The % inhibition is calculated by the formula : [ MC - ( MC + N ) ] MC - F × 100
  • Chronic treatment with morphine induces an increase in the motor activity of the rat, compared with the acute effect of the drug, by about 50% (128.6% as opposed to 80.3%). Chronic pre-treatment with neboglamine (30 mg/kg i.p for 7 days) succeeds in almost completely antagonizing (70.8%) the development of the inverse tolerance induced by the chronic treatment with morphine.
  • In a third experiment, we wished to study the effect of neboglamine both on the tolerance induced by a prolonged treatment with a benzodiazepine (diazepam) and on the abstinence crisis (“withdrawal”) produced by stopping the chronic treatment with diazepam.
  • The experiment was performed in an elevated zero maze in accordance with the procedure described by Shepard et al. (Psychopharmacology 116: 56-64, 1994) with minor changes.
  • The rat, placed in one of the closed quadrants, had free access to all 4 of the quadrants (2 open and 2 closed) for a period of 5 minutes. A compound with anxiolytic activity produces a percentage increase in the time spent in the free quadrants.
  • In the acute studies, the compounds were administered via the s.c. route 30 minutes before the experiment, whereas in the tolerance and “withdrawal” experiments, they were administered via the s.c. route twice a day for 7 days and then retested 40 hours after the end of the chronic treatment. The results thus obtained are collated in Table 3.
  • TABLE 3
    Effects of neboglamine on the tolerance and abstinence crisis
    induced by chronic treatment with diazepam in rats
    Time (seconds) % effect vs.
    Dose spent in the controls
    Treatment (mg/kg) s.c. open quadrants (saline)
    Physiological saline — 40 100.0
    Acute diazepam (D)  5 105 262.5
    Chronic diazepam (D-C) 5 × 2 (×7 days) + 5 (D) 58 145.0
    Acute neboglamine (N) 30 51 127.0
    Physiological (D-W) — 15 37.5
    Neboglamine+ (D-C) 30 × 2 (×7 days) + 30 + 5 (D) 77 192.5
    Neboglamine (D-W) — 44 110.0
    Note:
    Physiological (D-W) is the group treated with diazepam for 7 days and retested 40 hours later with physiological saline.
    Neboglamine (D-W) is the group treated with diazepam and neboglamine for 7 days and retested 40 hours later with physiological saline
  • 5 mg/kg s.c. of diazepam produce a significant anxiolytic effect (i.e. an increase in residence in the open quadrants): 262.5% compared with the control group.
  • The treatment continued for 7 days induces tolerance with a decrease in the anxiolytic effect from 262.5% to 145% compared with the control group. Neboglamine displays non-significant anxiolytic activity (127% compared with the controls). However, its co-administration with diazepam does not reduce tolerance (192.5% effect compared with the control). In addition, the co-administration of neboglamine was shown to inhibit the abstinence crisis induced by stoppage of the chronic treatment with diazepam [110% of effect for the group N-(D-W) as opposed to 37.5% of effect for the group (D-W)].
  • In accordance with that presented above, a subject of the invention is pharmaceutical compositions comprising as active principle neboglamine or the racemic mixture thereof, in native form or pharmaceutically acceptable salts thereof.
  • Pharmaceutical formulations for using the compounds according to the invention may be prepared using conventional techniques. The formulations include those suitable for oral use, for instance capsules, tablets, suspensions, emulsions, solutions; sterile solutions for parenteral use (including subcutaneous, intramuscular and intravenous administration), or preparations for topical or rectal use or other forms suitable for obtaining the desired therapeutic effect, for example solid formulations for oral use with delayed action, which allow a slow release of the active principle over time. Substances commonly used in the pharmaceutical field as excipients, binders, disintegrants and substances capable of stimulating transdermal absorption may be used together with the active principle in the pharmaceutical formulation.
  • Neboglamine compounds, such as the racemic mixture thereof, may thus be used in native form or as pharmaceutically acceptable salts. In the case of neboglamine, it is preferably the sodium or potassium salt or the hydrochloride.
  • The effective therapeutic amount of neboglamine to be used for the treatment of drug-induced toxicodependency should be between 10 and 600 mg and preferably from 30 to 300 mg per day of active principle, depending on the specific conditions of the treated patient, and the individual response to the treatment, the age and the weight of the patient.

Claims (12)

1. Use of neboglamine, (S)-4-amino-N(4,4-dimethylcyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the treatment of toxicodependency induced by drugs.
2. Use of neboglamine, the racemic mixture thereof or a pharmaceutically acceptable salt thereof for the preparation of a medicament for use in the therapeutic treatment of drug-induced abstinence crises.
3. Use of neboglamine, the racemic mixture thereof or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the therapeutic treatment of drug-induced tolerance phenomena.
4. Use according to any of claim 1, wherein said medicament also comprises pharmaceutically acceptable inactive ingredients, selected from the group consisting of vehicles, binders, flavourings, sweeteners, disintegrants, preserving agents and humectants and mixtures thereof, or ingredients that facilitate the oral, parenteral, transdermal, transmucosal or rectal adsorption and that allow time-controlled release of the active substances.
5. The use according to claim 1, wherein neboglamine is administered in a therapeutically effective amount of from 10 to 600 mg/day.
6. The use according to claim 1, wherein neboglamine is administered in a therapeutically effective amount of from 30 to 300 mg/day.
7. The use according to claim 1, wherein said drug is a CNS sedative, a stimulant or a hallucinogen.
8. The use according to claim 7, wherein said CNS sedative is selected from opiates, barbiturates, benzodiazepines and alcohol.
9. The use according to claim 7, wherein said stimulants are selected from amphetamines and cocaine.
10. The use according to claim 7, wherein said hallucinogens are selected from LSD, mescaline, cannabis (marijuana) or phencyclidine.
11. Use according to claim 2, wherein said medicament also comprises pharmaceutically acceptable inactive ingredients, selected from the group consisting of vehicles, binders, flavourings, sweeteners, disintegrants, preserving agents and humectants and mixtures thereof, or ingredients that facilitate the oral, parenteral, transdermal, transmucosal or rectal adsorption and that allow time-controlled release of active substances.
12. Use according to claim 3, wherein said medicament also comprises pharmaceutically acceptable inactive ingredients, selected from the group consisting of vehicles, binders, flavourings, sweeteners, disintegrants, preserving agents and humectants and mixtures thereof, or ingredients that facilitate the oral, parenteral, transdermal, transmucosal or rectal adsorption and that allow time-controlled release of active substances.
US12/067,390 2005-10-04 2006-10-03 Use of Neboglamine in the Treatment of Toxicodependency Abandoned US20100197962A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITTO2005A000691 2005-10-04
IT000691A ITTO20050691A1 (en) 2005-10-04 2005-10-04 USE OF NEBOGLAMINS IN THE DRUG TREATMENT THERAPY
PCT/IB2006/053603 WO2007039869A2 (en) 2005-10-04 2006-10-03 Use of neboglamine in the treatment of toxicodependency

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/053603 A-371-Of-International WO2007039869A2 (en) 2005-10-04 2006-10-03 Use of neboglamine in the treatment of toxicodependency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/192,071 Division US8258185B2 (en) 2005-10-04 2011-07-27 Use of neboglamine in the treatment of toxicodependency

Publications (1)

Publication Number Publication Date
US20100197962A1 true US20100197962A1 (en) 2010-08-05

Family

ID=37814217

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/067,390 Abandoned US20100197962A1 (en) 2005-10-04 2006-10-03 Use of Neboglamine in the Treatment of Toxicodependency
US13/192,071 Expired - Fee Related US8258185B2 (en) 2005-10-04 2011-07-27 Use of neboglamine in the treatment of toxicodependency

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/192,071 Expired - Fee Related US8258185B2 (en) 2005-10-04 2011-07-27 Use of neboglamine in the treatment of toxicodependency

Country Status (10)

Country Link
US (2) US20100197962A1 (en)
EP (1) EP1940376B1 (en)
JP (1) JP2009510158A (en)
AT (1) ATE425748T1 (en)
AU (1) AU2006298393B2 (en)
CA (1) CA2624449C (en)
DE (1) DE602006005831D1 (en)
ES (1) ES2323982T3 (en)
IT (1) ITTO20050691A1 (en)
WO (1) WO2007039869A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147690A1 (en) * 2018-01-23 2019-08-01 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9024738D0 (en) * 1990-11-14 1991-01-02 Erba Carlo Spa A new method of treatment of tumor necroisis factor(tnf)-related diseases
GB9109007D0 (en) * 1991-04-26 1991-06-12 Merck Sharp & Dohme Therapeutic method
IT1264765B1 (en) * 1993-03-10 1996-10-04 Rotta Research Lab DERIVATIVES OF GLUTAMIC ACID AND ASPARTIC ACID, PROCEDURE FOR THEIR PREPARATION AND THEIR USE AS DRUGS ENHANCING THE
ITTO20040343A1 (en) * 2004-05-24 2004-08-24 Rotta Res Lab Spa USE OF NEBOGLAMINE (CR2249) AS A NEUROPSYCHOTIC AND NEUROPROTECTIVE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147690A1 (en) * 2018-01-23 2019-08-01 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
US10737198B2 (en) 2018-01-23 2020-08-11 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
US10835839B1 (en) 2018-01-23 2020-11-17 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
US11338222B2 (en) 2018-01-23 2022-05-24 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons

Also Published As

Publication number Publication date
WO2007039869A3 (en) 2007-07-05
EP1940376B1 (en) 2009-03-18
ES2323982T3 (en) 2009-07-28
WO2007039869A2 (en) 2007-04-12
US8258185B2 (en) 2012-09-04
ITTO20050691A1 (en) 2007-04-05
ATE425748T1 (en) 2009-04-15
JP2009510158A (en) 2009-03-12
DE602006005831D1 (en) 2009-04-30
CA2624449C (en) 2013-12-17
AU2006298393B2 (en) 2011-04-14
EP1940376A2 (en) 2008-07-09
CA2624449A1 (en) 2007-04-12
US20110288173A1 (en) 2011-11-24
AU2006298393A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
JP5698282B2 (en) Mixed ORL1 / μ-agonist for the treatment of pain
DK2224917T3 (en) Composition with nicotine and opipramol and its use
US20070099947A1 (en) Methods and compositions for the treatment of brain reward system disorders by combination therapy
US20020037925A1 (en) Treatment of addiction and addiction-related behavior
JP2002532393A (en) Exo-R-mecamylamine formulations and their use in therapy
ES2236551T3 (en) COMBINATION OF ACTIVE PRINCIPLES FOR THE MEDICAL TREATMENT OF TOXICOMANS.
BRPI0610663A2 (en) therapeutic use of nefopam and its analogs
Ramos et al. Studies on the role of dopamine D1 receptors in the development and expression of MDMA-induced behavioral sensitization in rats
JPS59501459A (en) Improved analgesic and anti-inflammatory compositions comprising caffeine and methods of use thereof
US20110224245A1 (en) Treatment Of Neurological Disorders Using Huperzine
US8258185B2 (en) Use of neboglamine in the treatment of toxicodependency
US5547956A (en) Pharmaceutical composition and the method for treating drug addicts' withdrawal syndromes and detoxifying addicts by the same
KR20180033201A (en) Antitussive compositions and methods
US20150110865A1 (en) Cns stimulant and opioid receptor antagonist combination as a non-addictive, non-aversive and synergistic anti-obesity treatment
CN112569237B (en) Application of combination or compound of imatinib and derivatives thereof and nicotine or analogues thereof in preventing and treating nicotine addiction and relapse
ES2285995T3 (en) COMBINATION FOR THE TREATMENT OF DEPRESSION AND ANXIETY CONTAINING AN NK-1 RECEIVER ANTAGONIST PENETRA IN THE SNC AND AN ANTIDEPRESSIVE OR ANSIOLITICAL AGENT.
KR20220113411A (en) Use of KV7 potassium channel openers for the treatment of pain
WO2021063387A1 (en) Use of composition of imatinib and derivative thereof in preparation of drug for preventing, treating and controlling addiction relapse
US8779003B2 (en) Method and composition for prolonging analgesic effect of local anesthetic
EA003557B1 (en) Analgesic regimen
CN112569355B (en) Application of imatinib and derivative thereof and addiction substance combined medicine or compound preparation in prevention and treatment of addiction and prevention and treatment of relapse
CN116421611A (en) Application of semen Ziziphi Spinosae saponin in preparing analgesic and drug for reducing addiction
Walsh Antihistamines (H1 receptor antagonists)
US8142800B1 (en) Oral high potency clinical anti-craving treatment and method of use
TW202024040A (en) Use of carbamate compound and combination comprising the same for the prevetion, alleviation or treatment of acute stress disorder or post traumatic stress disorder

Legal Events

Date Code Title Description
AS Assignment

Owner name: ROTTAPHARM S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAKOVEC, FRANCESCO;CASELLI, GIANFRANCO;ROVATI, LUCIO CLAUDIO;AND OTHERS;REEL/FRAME:024976/0509

Effective date: 20080430

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION